INT51803

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1995
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 14
Total Number 29
Disease Relevance 14.98
Pain Relevance 4.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Pde7a)
Anatomy Link Frequency
aorta 1
basal ganglia 1
heart 1
neutrophil 1
T cell 1
Pde7a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 2 99.64 Very High Very High Very High
aspirin 20 99.58 Very High Very High Very High
cytokine 11 99.58 Very High Very High Very High
anesthesia 3 99.50 Very High Very High Very High
adenocard 18 99.24 Very High Very High Very High
Inflammation 10 98.92 Very High Very High Very High
Hyperalgesia 6 98.70 Very High Very High Very High
Bioavailability 3 97.56 Very High Very High Very High
tolerance 30 96.52 Very High Very High Very High
antagonist 67 95.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 885 99.84 Very High Very High Very High
Chronic Disease 31 99.80 Very High Very High Very High
Myocardial Infarction 16 99.70 Very High Very High Very High
Multiple Sclerosis 16 99.32 Very High Very High Very High
INFLAMMATION 12 98.92 Very High Very High Very High
Erectile Dysfunction 74 98.88 Very High Very High Very High
Hyperalgesia 6 98.70 Very High Very High Very High
Increased Venous Pressure Under Development 121 98.56 Very High Very High Very High
Reprotox - General 2 202 98.32 Very High Very High Very High
Disease 145 98.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats.
Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with anesthesia
1) Confidence 0.59 Published 2001 Journal Eur. J. Pharmacol. Section Title Doc Link 11430921 Disease Relevance 0 Pain Relevance 0.13
As inhibition of phosphodiesterase type 5 results in the accumulation of guanosine 3'5'-cyclic monophosphate (cGMP), specific phosphodiesterase type 5 inhibitors are expected to have a vasodilator property similar to that of NO donors.
Negative_regulation (inhibition) of phosphodiesterase type 5
2) Confidence 0.59 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430921 Disease Relevance 0 Pain Relevance 0.03
We also examined whether the motor disturbances and the changes of CB1 receptors found in the basal ganglia of EAE rats disappear after the treatment with rolipram, an inhibitor of type IV phosphodiesterase able to supress EAE in different species.
Spec (whether) Negative_regulation (inhibitor) of type IV phosphodiesterase in basal ganglia associated with multiple sclerosis
3) Confidence 0.45 Published 2005 Journal Neurobiol. Dis. Section Abstract Doc Link 16242629 Disease Relevance 0.92 Pain Relevance 0.60
In this study we have evaluated the mechanisms mediating the prolonged hyperalgesia induced by administration of prostaglandin E2 plus rolipram, an inhibitor of type IV phosphodiesterase.
Negative_regulation (inhibitor) of type IV phosphodiesterase associated with hyperalgesia
4) Confidence 0.44 Published 1995 Journal Neuroscience Section Abstract Doc Link 7715785 Disease Relevance 0.45 Pain Relevance 0.23
To test this hypothesis, we examined the effect of methyl2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel specific phosphodiesterase type 5 inhibitor, on mean arterial pressure and mean circulatory filling pressure (an index of venodilation) compared with that of nitroglycerin and diltiazem in mecamylamine- and noradrenaline-treated anesthetized rats.
Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with noradrenaline
5) Confidence 0.43 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430921 Disease Relevance 0 Pain Relevance 0.05
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.
Negative_regulation (inhibitor) of phosphodiesterase type 5 inhibitor in aorta
6) Confidence 0.18 Published 2001 Journal Eur. J. Pharmacol. Section Title Doc Link 11137871 Disease Relevance 0 Pain Relevance 0.05
Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase.
Negative_regulation (inhibiting) of type III phosphodiesterase associated with adenocard
7) Confidence 0.16 Published 2008 Journal CNS neuroscience & therapeutics Section Abstract Doc Link 18482026 Disease Relevance 0.59 Pain Relevance 0.26
Based on existing studies of sildenafil, a related selective phosphodiesterase type 5 inhibitor in PAH, and the findings of initial pilot studies, tadalafil appears to have excellent potential to provide therapeutic benefit in patients with pulmonary hypertension.
Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with pulmonary hypertension
8) Confidence 0.15 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.80 Pain Relevance 0.03
Tadalafil is a selective phosphodiesterase type 5 inhibitor approved by the Food and Drug Administration (FDA) for the treatment of erectile dysfunction (Carson 2006; Doggrell 2007; Hatzimouratidis & Hatzichristou 2007).
Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with reprotox - general 2
9) Confidence 0.15 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.32 Pain Relevance 0
The clinical evidence in support of the use of sildenafil, another phosphodiesterase type 5 inhibitor in PAH, will be also be reviewed.


Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with pulmonary hypertension
10) Confidence 0.15 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.73 Pain Relevance 0
All three agents are highly potent inhibitors of phosphodiesterase type 5 (IC50 values for sildenafil, vardenafil, and tadalafil are 3.9, 0.7, and 5 nM, respectively), with distinct patterns of relative selectivity for other phosphodiesterase isoforms (Carson 2006; Doggrell 2007).
Negative_regulation (inhibitors) of phosphodiesterase type 5
11) Confidence 0.15 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.48 Pain Relevance 0
Tadalafil’s long elimination half-life and once-daily dosage schedule make this agent a suitable candidate for development in other chronic diseases in which inhibition of phosphodiesterase type 5 may provide clinical benefit.
Negative_regulation (inhibition) of phosphodiesterase type 5 associated with chronic disease
12) Confidence 0.15 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.76 Pain Relevance 0.04
In men with erectile dysfunction related to impaired nitric oxide signaling, augmentation of cyclic GMP signaling with pharmacologic inhibition of phosphodiesterase type 5 is associated with improved erectile function.
Negative_regulation (inhibition) of phosphodiesterase type 5 associated with reprotox - general 2
13) Confidence 0.15 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.34 Pain Relevance 0.04
Preliminary studies in patients with chronic heart failure indicate that phosphodiesterase type 5 inhibition is associated with improved hemodynamics, amelioration of endothelial dysfunction, and improved exercise tolerance (Katz et al. 2000; Guazzi et al. 2004; Patel & Katz 2005; Lewis et al. 2007).
Negative_regulation (inhibition) of phosphodiesterase type 5 in heart associated with tolerance and myocardial infarction
14) Confidence 0.13 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.66 Pain Relevance 0.05
Chronic phosphodiesterase type 5 inhibition may also provide clinical benefit in patients with Raynaud’s phenomenon (Fries et al. 2005).



Negative_regulation (inhibition) of phosphodiesterase type 5
15) Confidence 0.13 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.49 Pain Relevance 0.05
The selective inhibitor of phosphodiesterase type 5 (PDE 5), 5-[2-ethoxy-5-(morpholinylacetyl)phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one methanesulphanate monohydrate also enhanced stimulation-induced release of ACh.
Negative_regulation (inhibitor) of phosphodiesterase type 5
16) Confidence 0.12 Published 2001 Journal Eur. J. Neurosci. Section Abstract Doc Link 11683902 Disease Relevance 0 Pain Relevance 0.56
Of particular relevance to the discussion of tadalafil in the treatment of PAH, sildenafil is a selective phosphodiesterase type 5 inhibitor that is approved by the FDA for this indication (Hemnes & Champion 2006; Raja et al. 2006).
Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with pulmonary hypertension
17) Confidence 0.11 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.71 Pain Relevance 0.11
Since phosphodiesterase type 5 is highly expressed in pulmonary vascular tissues, agents that selectively inhibit phosphodiesterase type 5 activity induce pulmonary arterial vasodilatation, and are being developed for the treatment of PAH.


Negative_regulation (inhibit) of phosphodiesterase type 5 associated with pulmonary hypertension and increased venous pressure under development
18) Confidence 0.11 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.84 Pain Relevance 0.05
The purpose of this review is to evaluate the existing evidence for the use of tadalafil, a selective phosphodiesterase type 5 inhibitor, in PAH.


Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with pulmonary hypertension
19) Confidence 0.11 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.97 Pain Relevance 0.04
The potential clinical utility of selective pharmacologic inhibition of phosphodiesterase type 5 has been extensively evaluated in clinical trials in men with erectile dysfunction (Carson 2006; Doggrell 2007; Hatzimouratidis & Hatzichristou 2007).
Negative_regulation (inhibition) of phosphodiesterase type 5 associated with reprotox - general 2
20) Confidence 0.11 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.17 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox